Acute myeloid leukemia (AML) is a malignant tumor of the immature myeloid hematopoietic
cells in the bone marrow (BM). It is a highly heterogeneous disease, with rising morbidity …

The efficacy of macrophage-mediated inflammatory response relies on the coordinated
expression of key factors, which expression is finely regulated at both transcriptional and …

Acute myeloid leukemia (AML) is driven by leukemia stem cells (LSCs) that resist
conventional chemotherapy and are the major cause of relapse,. Hypomethylating agents …

In breast cancer, the increased stiffness of the extracellular matrix is a key driver of
malignancy. Yet little is known about the epigenomic changes that underlie the tumorigenic …

Background & Aims The cancer stem cells (CSCs) have important therapeutic implications
for multi-resistant cancers including hepatocellular carcinoma (HCC). Among the key …

Nuclear factor κB (NF-κB) is a transcriptional factor that regulates a battery of genes that are
critical to innate and adaptive immunity, cell proliferation, inflammation, and tumor …

The activation of nuclear factor-kappaB (NFΚB), a proinflammatory transcription factor, is a
commonly observed phenomenon in breast cancer. It facilitates the development of a …

Acute myeloid leukemia (AML) is a deadly hematologic malignancy characterized by the
uncontrolled growth of immature myeloid cells. Over the past several decades, we have …

Cancers that appear pathologically similar often respond differently to the same drug
regimens. Methods to better match patients to drugs are in high demand. We demonstrate a …

The ability to reprogram the transcriptional circuitry by remodeling the three-dimensional
structure of the genome is exploited by cancer cells to promote tumorigenesis. This …